Effect of High-Dose vs Standard-Dose Vitamin D Supplementation on Neurodevelopment of Healthy Term Infants: A Randomized Clinical Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Vitamin D may be important for neurodevelopment.

Who Took Part

The study group was 404 infants.

PubMed indexes the participants as infants and adults, both men and women.

This double-blind, interventional randomized clinical trial involved healthy infants born full-term between January 1, 2013, and June 30, 2014, at a maternity hospital in Helsinki, Finland, at the 60th northern latitude.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Two-year follow-up was conducted by May 30, 2016.

Data analysis was by the intention-to-treat principle.

Data were analyzed from November 1, 2020, to May 31, 2021.

What Was Measured

The subject headings attached to it are Brain, Infant Nutritional Physiological Phenomena and Vitamin D.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 404 infants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (JAMA network open), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.